US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

0QDU

Abliva Ab (0QDU)

Abliva Ab

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QDU

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
19/02/2020	02:03	PR Newswire (US)	NeuroVive Pharmaceutical AB Year End Report January - December 2019	LSE:0QDU	Abliva Ab
20/12/2019	08:44	PR Newswire (US)	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study	LSE:0QDU	Abliva Ab
16/12/2019	04:21	PR Newswire (US)	NeuroVive Announces Settlement in Dispute With CicloMulsion AG	LSE:0QDU	Abliva Ab
20/11/2019	02:04	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - September 2019	LSE:0QDU	Abliva Ab
21/08/2019	01:55	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - June 2019	LSE:0QDU	Abliva Ab
20/08/2019	06:23	PR Newswire (US)	Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019	LSE:0QDU	Abliva Ab
27/07/2019	06:38	PR Newswire (US)	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation	LSE:0QDU	Abliva Ab
04/07/2019	07:46	PR Newswire (US)	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study	LSE:0QDU	Abliva Ab
21/05/2019	01:45	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - March 2019	LSE:0QDU	Abliva Ab
10/05/2019	01:48	PR Newswire (US)	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA	LSE:0QDU	Abliva Ab
25/03/2019	04:48	PR Newswire (US)	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report	LSE:0QDU	Abliva Ab
07/03/2019	02:07	PR Newswire (US)	NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue	LSE:0QDU	Abliva Ab
21/02/2019	01:52	PR Newswire (US)	NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds	LSE:0QDU	Abliva Ab
15/11/2018	05:25	PR Newswire (US)	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders	LSE:0QDU	Abliva Ab
31/10/2018	03:07	PR Newswire (US)	NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1	LSE:0QDU	Abliva Ab
04/10/2018	01:50	PR Newswire (US)	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI	LSE:0QDU	Abliva Ab
11/12/2017	04:41	PR Newswire (US)	NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333	LSE:0QDU	Abliva Ab

Showing the most relevant articles for your search:LSE:0QDU

1

Verizon Communications

Euro vs US Dollar

JP Morgan Chase

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones